Market Closed -
Nasdaq
04:00:00 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
160
USD
|
-0.83%
|
|
-1.71%
|
+29.01%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
958.5
|
1,182
|
1,742
|
2,040
|
3,499
|
4,571
|
-
|
-
|
Enterprise Value (EV)
1 |
774.3
|
918.1
|
1,304
|
1,661
|
2,905
|
3,977
|
3,772
|
3,427
|
P/E ratio
|
-46.2
x
|
-35.1
x
|
-22.3
x
|
-14.4
x
|
318
x
|
70.8
x
|
29.1
x
|
18.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
69
x
|
17.2
x
|
10.7
x
|
7.58
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
57.3
x
|
14.9
x
|
8.85
x
|
5.68
x
|
EV / EBITDA
|
-36.3
x
|
-29.5
x
|
-19.9
x
|
-11.5
x
|
-27.4
x
|
59
x
|
23
x
|
11.5
x
|
EV / FCF
|
-
|
-22.4
x
|
-11.2
x
|
-10.8
x
|
-28.9
x
|
30.5
x
|
15.7
x
|
9.93
x
|
FCF Yield
|
-
|
-4.46%
|
-8.92%
|
-9.25%
|
-3.46%
|
3.28%
|
6.36%
|
10.1%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
17,308
|
19,708
|
24,906
|
25,748
|
28,206
|
28,558
|
-
|
-
|
Reference price
2 |
55.38
|
60.00
|
69.95
|
79.22
|
124.1
|
160.0
|
160.0
|
160.0
|
Announcement Date
|
3/10/20
|
3/1/21
|
2/28/22
|
2/27/23
|
2/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
50.7
|
266.4
|
427.9
|
610
|
EBITDA
1 |
-21.33
|
-31.15
|
-65.51
|
-144.1
|
-106
|
67.35
|
164.3
|
298.3
|
EBIT
1 |
-22.08
|
-33
|
-68.28
|
-145.2
|
-109.7
|
55.28
|
174
|
306.1
|
Operating Margin
|
-
|
-
|
-
|
-
|
-216.43%
|
20.75%
|
40.65%
|
50.19%
|
Earnings before Tax (EBT)
1 |
-19.09
|
-32.17
|
-69.57
|
-140
|
12.9
|
72.98
|
211
|
340.2
|
Net income
1 |
-19.09
|
-32.17
|
-69.57
|
-140
|
10.93
|
62.79
|
159.8
|
264.5
|
Net margin
|
-
|
-
|
-
|
-
|
21.56%
|
23.57%
|
37.35%
|
43.37%
|
EPS
2 |
-1.200
|
-1.710
|
-3.130
|
-5.490
|
0.3900
|
2.261
|
5.506
|
8.630
|
Free Cash Flow
1 |
-
|
-40.93
|
-116.3
|
-153.5
|
-100.6
|
130.4
|
239.8
|
345.1
|
FCF margin
|
-
|
-
|
-
|
-
|
-198.43%
|
48.94%
|
56.05%
|
56.58%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
193.61%
|
145.98%
|
115.71%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
207.68%
|
150.06%
|
130.46%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/20
|
3/1/21
|
2/28/22
|
2/27/23
|
2/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
8.556
|
42.14
|
45.25
|
64.71
|
75.42
|
82.44
|
-
|
-
|
EBITDA
1 |
-21.09
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
4.298
|
9.545
|
31.2
|
37.83
|
39.98
|
-
|
-
|
EBIT
1 |
-21.88
|
-25.22
|
-28.75
|
-31.45
|
-34.77
|
-48.82
|
-38.05
|
-25.99
|
3.138
|
5.816
|
18.59
|
23.58
|
25.43
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-303.8%
|
7.45%
|
12.85%
|
28.72%
|
31.26%
|
30.85%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-21.81
|
-49.96
|
-28.11
|
-29.85
|
-32.05
|
-45.3
|
-33.21
|
80.75
|
10.66
|
0.932
|
18.35
|
24.25
|
24.2
|
-
|
-
|
Net income
1 |
-21.81
|
-49.96
|
-28.11
|
-29.85
|
-32.05
|
-45.3
|
-33.21
|
80.75
|
8.692
|
0.932
|
16.62
|
21.55
|
21.78
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
943.75%
|
20.63%
|
2.06%
|
25.68%
|
28.57%
|
26.42%
|
-
|
-
|
EPS
2 |
-0.9500
|
-1.990
|
-1.100
|
-1.170
|
-1.250
|
-1.760
|
-1.250
|
2.790
|
0.3100
|
0.0300
|
0.6214
|
0.7300
|
0.7500
|
1.410
|
1.270
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/22
|
5/9/22
|
8/8/22
|
11/7/22
|
2/27/23
|
5/8/23
|
8/7/23
|
11/6/23
|
2/26/24
|
5/6/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
184
|
264
|
438
|
379
|
594
|
594
|
799
|
1,144
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-40.9
|
-116
|
-154
|
-101
|
130
|
240
|
345
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-15.7%
|
-25.1%
|
-11.4%
|
12.8%
|
18.7%
|
17.6%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-
|
-2.160
|
-3.950
|
-3.200
|
2.940
|
4.020
|
-
|
Capex
1 |
-
|
14.8
|
68.3
|
0.05
|
11.8
|
7.3
|
10
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
23.27%
|
2.74%
|
2.35%
|
-
|
Announcement Date
|
3/10/20
|
3/1/21
|
2/28/22
|
2/27/23
|
2/26/24
|
-
|
-
|
-
|
Average target price
189
USD Spread / Average Target +18.09% Consensus |
1st Jan change
|
Capi.
|
---|
| +29.01% | 4.57B | | +11.60% | 106B | | -4.68% | 24.28B | | -0.29% | 21.96B | | -8.61% | 18.16B | | -42.12% | 16.37B | | -17.47% | 15.56B | | +2.77% | 13.63B | | +34.58% | 12.27B | | +77.64% | 8.87B |
Bio Therapeutic Drugs
|